0.7626

5.07% 0.0368

After Hours: .77 0.0074 +0.97%

Precigen Inc (PGEN)

Overview News Price History Option Chain Financials Discussions Forecast

Precigen Inc stock is traded at $0.7626, with a volume of 1.62M. It is up +5.07% in the last 24 hours and down -8.86% over the past month. Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Previous Close:

$0.7258

Open:

$0.73

24h Volume:

1.62M

Relative Volume:

1.87

Market Cap:

$223.34M

Revenue:

$6.23M

Net Income/Loss:

$-95.90M

P/E Ratio:

5.084

EPS:

0.15

Net Cash Flow:

$-68.47M

1W Performance:

+12.93%

1M Performance:

-8.86%

6M Performance:

-50.16%

1Y Performance:

-30.67%

1-Day Range:

$0.71

$0.7721

1-Week Range:

$0.6513

$0.7773

52-Week Range:

$0.6513

$1.93

Precigen Inc Stock (PGEN) Company Profile

Name

Precigen Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

301-556-9900

Address

20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD

Employee

202

Twitter

@precigen

Next Earnings Date

2024-11-07

Latest SEC Filings

PGEN's Discussions on Twitter

Compare PGEN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PGEN Precigen Inc	0.7626	223.34M	6.23M	-95.90M	-68.47M	-0.39
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Precigen Inc Stock (PGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight
Feb-25-21	Initiated	Stifel	Buy
Feb-22-21	Initiated	Wells Fargo	Overweight
Feb-18-21	Initiated	B. Riley Securities	Buy
May-08-20	Initiated	H.C. Wainwright	Buy

View All

Precigen Inc Stock (PGEN) Latest News

03:14 AM

Fmr LLC Has $327,000 Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World

03:14 AM

Dec 20, 2024

Analysts Update Their Estimates For Precigen Inc - Stocks Register

Dec 20, 2024

Dec 17, 2024

Metastatic Triple Negative Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc - Barchart

Dec 17, 2024

Further weakness as Precigen (NASDAQ:PGEN) drops 16% this week, taking five-year losses to 89% - Simply Wall St

Dec 17, 2024

Dec 15, 2024

Precigen's SWOT analysis: biotech firm's stock rides on PRGN-2012 hopes - Investing.com

Dec 15, 2024

Dec 13, 2024

PGEN Stock Touches 52-Week Low at $0.71 Amid Market Challenges - Investing.com Canada

Dec 13, 2024

Dec 11, 2024

Precigen to Participate in the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online

Dec 11, 2024

Dec 08, 2024

Precigen to Participate in the Stifel 2024 Healthcare Conference - The Eastern Progress Online

Dec 08, 2024

Dec 05, 2024

PGEN Stock Plummets to 52-Week Low at $0.77 Amid Market Challenges - Investing.com Nigeria

Dec 05, 2024

PGEN Stock Plummets to 52-Week Low at $0.77 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 05, 2024

Dec 01, 2024

Precigen (STU:I5X) Shares Outstanding (EOP) : 292.87 Mil (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 01, 2024

Nov 29, 2024

Bioinformatics Market to Grow by USD 13.2 Billion (2024-2028), Lower Genetic Sequencing Costs Drive Revenue, Report Highlights AI's Role in TransformationTechnavio - The Malaysian Reserve

Nov 29, 2024

Nov 25, 2024

Precigen's SWOT analysis: biotech stock focuses on RRP treatment - Investing.com

Nov 25, 2024

Precigen's SWOT analysis: biotech stock focuses on RRP treatment By Investing.com - Investing.com Australia

Nov 25, 2024

Nov 24, 2024

Precigen Reports Q3 2024 Financial Results - MSN

Nov 24, 2024

Nov 20, 2024

Insiders Sold Precigen Prematurely At US$1.41 With Stock Trading Higher - Simply Wall St

Nov 20, 2024

Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86% - Yahoo Finance

Nov 20, 2024

PGEN stock touches 52-week low at $0.78 amid market challenges - Investing.com Canada

Nov 15, 2024

HC Wainwright Reiterates Buy Rating for Precigen (NASDAQ:PGEN) - MarketBeat

Nov 15, 2024